Academician Ding Jian of the Chinese Academy of Engineering visited and exchanged views
On the morning of March 3rd, Academician Ding Jian of the Chinese Academy of Engineering and his party came to the Jianggan Branch of our institute for research and exchange, accompanied by Chen Yi, researcher of the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Zhang Dan, vice dean of the School of Medicine of Zhejiang University, Lin Aifu, vice president of the "Belt and Road" International Medical College, Zhu Hong, professor of the School of Pharmacy, and Zhen Ping, deputy director of the Base Office of the Academy of Science and Technology. Wang Jian'an, secretary of the party committee of our hospital, Wang Weilin, president of our hospital, Ding Kefeng, vice president of the hospital, and personnel of relevant functional departments accompanied the investigation.
After visiting the Jianggan Campus and listening to the briefing on the basic situation, historical evolution, scientific and technological innovation and oncology discipline of our hospital, Academician Ding Jian said that in the long history of the Second Hospital of Zhejiang University, the "3H" concept left by the older president of Meteng left a very deep impression on him, and he believed that under the influence of the concept of "Head knowledge, Hand skills, and Heart benevolence", every medical staff can benefit the people and shine in their respective posts. He also said that this trip to Zhejiang Has gained a lot, and he hopes to have the opportunity to cooperate with such an excellent hospital.
Congratulations to Professor Yuan Ying on her election as the vice chairman of the Colorectal Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO).
On February 27, 2021, Professor Ying Yuan, Director of the Department of Oncology of our hospital, was elected as the vice chairman of the Colorectal Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO). This is another good news for the colorectal cancer team of our hospital after Professor Zhang Suzhan was elected as the chairman of the first CSCO Colorectal Cancer Expert Committee and Professor Ding Kefeng was elected as the chairman-designate of the Colorectal Cancer Professional Committee of the Chinese Anti-Cancer Association.
Postmenopausal osteoporosis should pay attention to these points!
List of key updates to the 2020 AACE and ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis
In May 2020, the American Association of Endocrinologists (AACE) and the American Endocrine Association (ACE) Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis (hereinafter referred to as the AACE/ACE Guidelines) were revised based on the latest clinical evidence based on the 2016 edition of the guidelines, with the aim of hoping to reduce the risk of osteoporosis-related fractures and thereby maintain the quality of life of osteoporosis patients. The guidelines incorporate optimal evidence to support it and take into account the economic impact of the disease and the need for postmenopausal osteoporosis treatment and its effectiveness assessment.
Key updates to this guide (see flowchart for details):
⚫ Women with postmenopausal osteoporosis can be stratified according to high- and very high-risk features, including a history of previous fractures. The stratification of the patient determines the choice of initial drug and the duration of treatment.
⚫ The new osteogenesis drug Romosozumab is included in the treatment flow chart.
Q1: At what age should the risk of osteoporosis be assessed?
R1: Guidelines recommend that all postmenopausal women aged ≥ 50 years should have a risk assessment of osteoporosis.
Q2: What are the basic measures to maintain bone health?
R2: Vitamin D3 supplementation with a daily intake of 1000-2000 international units (IU), maintain adequate dietary calcium intake, limit alcohol intake, quit smoking, and advise patients to maintain active physical activity.
Q3: Which patients need medication?
R3: Medication is highly recommended in patients with osteopenia or low bone mass who have a history of hip or vertebral fragility fractures.
AACE/ACE2020
Flowchart of osteoporosis in postmenopausal women
Click on the image for a larger view
Interpreter: Li Wanli
Chief Physician of the Department of Orthopedics, Second Hospital of Zhejiang University
He is a visiting scholar at the University of California, Reagan Medical Center (UCLA), Texas Spine Surgery Center (TBI), and Cleveland Clinic
Member of the North American Association of Spine Surgery (NASS) and AOSpine of the United States. He is a member of the Trauma Branch of the China Association for the Promotion of International Exchanges in Healthcare, a youth member of the Zhejiang Spinal Cord Injury Professional Committee, and a deputy leader of the Spine Minimally Invasive Group of the Osteoporosis Professional Committee of the Zhejiang Rehabilitation Medical Association.
Focus on the minimally invasive surgical treatment of osteoporosis with pathological fractures of the spine, the drugs and comprehensive treatment of primary senile osteoporosis and postmenopausal osteoporosis.
Clinic hours: Wednesday morning Osteoporosis Specialist Clinic (Binjiang Campus)
Newly discovered "transostes" may be a treatment
Osteoporosis or bone metastatic cancer offers new targets
Our bones are constantly changing throughout their lives, and in order to support bone growth, maintenance and repair of damage, special cells on the surface of bones break down old bone tissue and prompt its repair. This particular cell is called osteoclast. Osteoclasts are multinucleated giant cells that differentiate from monocytes and can absorb bone tissue, ensuring the development and continuous remodeling of bones. Osteoclast abnormalities are closely related to other bone diseases such as osteoporosis and bone metastatic cancer.
Australia's Garvan Medical Research Institute recently published an article in cell, when they used in vivo imaging technology to look deeply into the internal situation of living bone tissue, found that osteoclasts do something unusual - they divide into smaller cells, and then combine to form osteoclasts. This breaks through previous understanding of osteoclasts. The researchers named the new cell "osteomorphs." "The process is completely new for us. Until now, it has been thought that osteoclasts experience cell death after completing their work, but we have seen osteoclasts recycle by dividing and recombining together. The paper's first author, Dr. Michelle McDonald, said.
This newly discovered cell may help us find new ways to treat osteoporosis or bone metastatic cancer.
Interpreter: Qu Hao
Attending Physician of the Department of Orthopedics, Second Hospital of Zhejiang University, Ph.D
Member of the Bone Tumor and Bone Metastases Professional Committee of the Chinese Anti-Cancer Association
Research Directions
Clinical diagnosis and treatment: bone and soft tissue tumors, spinal metastatic carcinoma, metastatic bone tumors, minimally invasive treatment of spinal tumors.
Basic research: mechanism of osteosarcoma metastasis, osteoclast and osteoporosis, mechanism of bone metastatic carcinoma.
Clinic hours: Monday afternoon Spinal Cancer Specialist Clinic (Binjiang Campus)
In addition, if you need advanced bone tumor patients who need immunization or targeted therapy, you can hang up the "Binjiang Osteochondroma Precision Targeted Immunotherapy" by Li Binghao, attending physician of Binjiang Hospital on Tuesday afternoon (Binjiang Branch) (click to register directly)
The 42nd issue of "Guangji Week" has come to an end
Thank you to all readers for your support
If there are relevant suggestions or comments
Please leave a message below
We sincerely hope
Readers can get through
This window of the hospital
See Chinese science and technology
Changing
Health undertakings
Progress takes off
It can also be truly perceived
Social cooling and warmth
Feel the hospital's commitment to health
Diligent pursuit
Responsible editor| Tong Xiaoxian